Watch VIR. Know when insiders buy.
One email the day a filing lands. Free.
VIR
Vir Biotechnology, Inc.
11.17
−0.12 −1.06%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
30
FLAG · shorts 30
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.9BP/E —DIV YIELD —FCF YIELD -10.77%REV TTM $303.2M +1495.9%NET INCOME −$251.7MNET CASH —52W 5.12 – 11.63SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $238.9M | +19582.5% | 100.0% | $73.5M | $80.1M | — | 0.47 | $123.3M | $32K | $123.3M | Aug 5 |
| Q1 2026 · Mar 31 | −$29K | −101.0% | — | −$132.3M | −$125.7M | — | -0.85 | −$132.4M | $390K | −$132.8M | May 7 |
| Q4 2025 · Dec 31derived | $64.1M | +417.8% | — | −$47.9M | −$42.9M | — | -0.30 | −$25.9M | $348K | −$26.2M | Feb 23 |
| Q3 2025 · Sep 30 | $240K | −89.9% | — | −$173.4M | −$163.1M | — | -1.17 | −$167.6M | $317K | −$167.9M | Nov 5 |
| Q2 2025 · Jun 30 | $1.2M | −60.5% | 99.1% | −$118.4M | −$111M | — | -0.80 | −$120.2M | $2.5M | −$122.8M | Aug 5 |
| Q1 2025 · Mar 31 | $3M | −94.6% | 100.0% | −$139.5M | −$121M | — | -0.88 | −$78.1M | $1.6M | −$79.7M | May 7 |
| Q4 2024 · Dec 31derived | $12.4M | −26.3% | 94.5% | −$117.2M | −$104.6M | — | -0.76 | −$87.6M | $2M | −$89.6M | Feb 23 |
| Q3 2024 · Sep 30 | $2.4M | −9.8% | 97.9% | −$231.3M | −$213.7M | — | -1.56 | −$171.5M | $2.8M | −$174.2M | Nov 5 |
| Q2 2024 · Jun 30 | $3.1M | — | 98.3% | −$158.6M | −$138.4M | — | -1.02 | −$77.8M | $666K | −$78.5M | Aug 6 |
| Q1 2024 · Mar 31 | $56.4M | — | 99.9% | −$80.1M | −$65.3M | — | -0.48 | −$109.4M | $1.9M | −$111.3M | May 8 |
| Q4 2023 · Dec 31derived | $16.8M | — | 95.2% | −$139M | −$116M | — | -0.86 | −$107.9M | $1.5M | −$109.5M | Feb 23 |
| Q3 2023 · Sep 30 | $2.6M | — | 98.6% | −$186.7M | −$163.4M | — | -1.22 | −$155.8M | $3.7M | −$159.5M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $68.6M | 100.0% | −$479.3M | −$438M | -638.9% | -3.16 | −$391.8M | $4.8M | −$396.6M | — | — |
| FY2024 · to Dec 31 | $74.2M | 98.9% | −$587.2M | −$522M | -703.4% | -3.83 | −$446.4M | $7.3M | −$453.7M | — | — |
| FY2023 · to Dec 31 | $86.2M | 96.8% | −$684.3M | −$615.1M | -713.7% | -4.59 | −$778.8M | $21.6M | −$800.4M | — | — |
| FY2022 · to Dec 31 | $1.6B | 90.9% | $833.1M | $515.8M | 31.9% | 3.83 | $1.7B | $68M | $1.6B | — | — |
| FY2021 · to Dec 31 | $1.1B | 94.0% | $420.8M | $528.6M | 48.3% | 3.96 | −$47.6M | $21.8M | −$69.4M | — | — |
| FY2020 · to Dec 31 | $76.4M | 100.0% | −$297M | −$298.7M | -391.1% | -2.51 | −$190.9M | $6.5M | −$197.5M | — | — |
Every number comes from Vir Biotechnology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.